Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.

Abstract

Etanercept, a soluble tumor necrosis factor (TNF) receptor, provided a well tolerated and effective treatment option for some patients even when infliximab, a monoclonal antibody to TNF, had been ineffective.